SG11201809626PA - Modulation of lipid metabolism for protein production - Google Patents

Modulation of lipid metabolism for protein production

Info

Publication number
SG11201809626PA
SG11201809626PA SG11201809626PA SG11201809626PA SG11201809626PA SG 11201809626P A SG11201809626P A SG 11201809626PA SG 11201809626P A SG11201809626P A SG 11201809626PA SG 11201809626P A SG11201809626P A SG 11201809626PA SG 11201809626P A SG11201809626P A SG 11201809626PA
Authority
SG
Singapore
Prior art keywords
international
kent
lipid metabolism
modulation
pct
Prior art date
Application number
SG11201809626PA
Other languages
English (en)
Inventor
James Budge
Christopher Mark Smales
Tanya Knight
Robert Young
Original Assignee
Lonza Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Ag filed Critical Lonza Ag
Publication of SG11201809626PA publication Critical patent/SG11201809626PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0097Oxidoreductases (1.) acting on reduced flavodoxin as donor (1.19)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0681Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083Miscellaneous (1.14.99)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y114/00Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/19Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water (1.14.19)
    • C12Y114/19001Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11201809626PA 2016-05-03 2017-05-03 Modulation of lipid metabolism for protein production SG11201809626PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330973P 2016-05-03 2016-05-03
PCT/EP2017/060484 WO2017191165A1 (en) 2016-05-03 2017-05-03 Modulation of lipid metabolism for protein production

Publications (1)

Publication Number Publication Date
SG11201809626PA true SG11201809626PA (en) 2018-11-29

Family

ID=58745198

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809626PA SG11201809626PA (en) 2016-05-03 2017-05-03 Modulation of lipid metabolism for protein production

Country Status (13)

Country Link
US (3) US10655111B2 (enExample)
EP (1) EP3452608B1 (enExample)
JP (1) JP6959942B2 (enExample)
KR (1) KR102536221B1 (enExample)
CN (1) CN109415748A (enExample)
AU (1) AU2017259010B2 (enExample)
CA (1) CA3023038C (enExample)
EA (1) EA201892503A1 (enExample)
ES (1) ES2938626T3 (enExample)
IL (2) IL294241B2 (enExample)
MX (1) MX2018013499A (enExample)
SG (1) SG11201809626PA (enExample)
WO (1) WO2017191165A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2938626T3 (es) 2016-05-03 2023-04-13 Lonza Ag Modulación del metabolismo de los lípidos para la producción de proteínas
ES2871818T3 (es) * 2018-02-02 2021-11-02 Lonza Ag Métodos de selección celular y modificación del metabolismo celular
US20210324366A1 (en) * 2018-07-11 2021-10-21 Cornell University Supported plant plasma membrane lipid bilayer on-a-chip
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113348248B (zh) * 2018-10-24 2024-12-31 思兰克斯有限公司 表达系统、重组细胞及其用途
JP7574206B2 (ja) 2019-03-20 2024-10-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ステロール調節エレメント結合転写因子1(srebf1)阻害剤による上昇した脂質レベルの治療
CN110317799B (zh) * 2019-07-18 2026-04-03 江南大学 一种人源岩藻糖转移酶8的原核表达方法及其产品
US20220403398A1 (en) 2019-11-14 2022-12-22 Lonza Ltd Methods of cell selection
CN115029307A (zh) * 2022-07-28 2022-09-09 吉林大学 一种延缓MSCs衰老的方法
WO2026062080A1 (en) 2024-09-17 2026-03-26 Ares Trading S.A. Cell having increased secretion capabilities and method of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
AU2002321989A1 (en) 2001-02-02 2002-12-03 Bayer Corporation Methods of modulating surfactant phospholipid production
JP2007500016A (ja) * 2003-06-11 2007-01-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド 培養においてタンパク質生成を増大させるための方法
JP4783359B2 (ja) 2004-04-16 2011-09-28 ディーエスエム アイピー アセッツ ビー.ブイ. 真菌細胞において遺伝子を発現させるための真菌プロモーター
EP1915394B1 (en) * 2005-05-20 2021-01-27 Lonza Biologics plc. High-level expression of recombinant antibody in a mammalian host cell
US20080182249A1 (en) * 2006-09-01 2008-07-31 Fox Brian G Expression systems for mammalian and mycobacterial desaturases
EP2209891A1 (en) 2007-11-13 2010-07-28 Boehringer Ingelheim Pharma GmbH & Co. KG Improving the secretory capacity in host cells
US8809559B2 (en) * 2008-11-18 2014-08-19 Commonwelath Scientific And Industrial Research Organisation Enzymes and methods for producing omega-3 fatty acids
HUE043103T2 (hu) * 2013-02-01 2019-08-28 Selexis Sa Fokozott transzgén expresszió és processzálás
CN105849265B (zh) * 2013-08-06 2021-03-26 英国龙沙生物医药股份有限公司 用于产生供生产重组蛋白的哺乳动物生产细胞的物品和方法
ES2938626T3 (es) * 2016-05-03 2023-04-13 Lonza Ag Modulación del metabolismo de los lípidos para la producción de proteínas

Also Published As

Publication number Publication date
CA3023038A1 (en) 2017-11-09
BR112018072434A2 (pt) 2019-02-19
EA201892503A1 (ru) 2019-09-30
US10655111B2 (en) 2020-05-19
US11434474B2 (en) 2022-09-06
EP3452608A1 (en) 2019-03-13
IL294241B2 (en) 2023-10-01
AU2017259010A1 (en) 2018-11-22
US20200231944A1 (en) 2020-07-23
AU2017259010B2 (en) 2021-04-22
WO2017191165A1 (en) 2017-11-09
KR20190003651A (ko) 2019-01-09
EP3452608B1 (en) 2022-11-30
CN109415748A (zh) 2019-03-01
KR102536221B1 (ko) 2023-05-23
CA3023038C (en) 2023-03-14
ES2938626T3 (es) 2023-04-13
JP2019514399A (ja) 2019-06-06
IL262646A (en) 2018-12-31
IL294241B1 (en) 2023-06-01
IL294241A (en) 2022-08-01
IL262646B (en) 2022-08-01
JP6959942B2 (ja) 2021-11-05
MX2018013499A (es) 2019-09-11
US20230047838A1 (en) 2023-02-16
US20170321194A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
SG11201903407XA (en) Secretable variant immunomodulatory proteins and engineered cell therapy
SG11201909203WA (en) Tissue selective transgene expression
SG11201805805VA (en) Recombinogenic nucleic acid strands in situ
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201810286WA (en) Variable diameter bioreactors
SG11201810975UA (en) Method for stabilizing proteins
SG11201807378SA (en) Trans-replicating rna
SG11201907754RA (en) Anti-phf-tau antibodies and uses thereof
SG11201901563UA (en) De novo synthesized nucleic acid libraries
SG11201804400SA (en) Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
SG11201900753VA (en) A method of isolating mesenchymal stem cells from umbilical cord amniotic membrane using a cell culture medium
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201905508VA (en) Hsd17b13 variants and uses thereof
SG11201907646YA (en) Proteins binding her2, nkg2d and cd16
SG11201810048VA (en) Tri-segmented pichinde viruses as vaccine vectors
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201808398PA (en) Cell line for recombinant protein and/or viral vector production
SG11201909087PA (en) Perfusion medium
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201907648XA (en) Proteins binding gd2, nkg2d and cd16
SG11201807881VA (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
SG11201900231RA (en) Culture media for culturing pluripotent stem cells in suspension
SG11201809903WA (en) Method for purification and activation of botulinum neurotoxin